3/25
04:05 pm
tenx
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Low
Report
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
3/21
02:03 am
tenx
Tenax Therapeutics, Inc. (NASDAQ: TENX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Tenax Therapeutics, Inc. (NASDAQ: TENX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/13
02:08 am
tenx
Tenax Therapeutics, Inc. (NASDAQ: TENX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Tenax Therapeutics, Inc. (NASDAQ: TENX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
3/10
12:14 pm
tenx
Tenax Therapeutics, Inc. (NASDAQ: TENX) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Tenax Therapeutics, Inc. (NASDAQ: TENX) had its "outperform" rating re-affirmed by analysts at William Blair.
3/10
12:03 pm
tenx
Tenax Therapeutics, Inc. (NASDAQ: TENX) was given a new $20.00 price target on by analysts at Leerink Partners.
Low
Report
Tenax Therapeutics, Inc. (NASDAQ: TENX) was given a new $20.00 price target on by analysts at Leerink Partners.
3/5
09:56 am
tenx
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF [Yahoo! Finance]
Medium
Report
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF [Yahoo! Finance]
3/5
08:47 am
tenx
Tenax Therapeutics Announces $25 Million Private Placement
Medium
Report
Tenax Therapeutics Announces $25 Million Private Placement
3/5
08:42 am
tenx
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
Low
Report
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
3/3
08:06 am
tenx
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference [Yahoo! Finance]
Medium
Report
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference [Yahoo! Finance]
1/31
10:00 am
tenx
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference [Yahoo! Finance]
Low
Report
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference [Yahoo! Finance]
1/31
09:00 am
tenx
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
Low
Report
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
1/22
08:00 am
tenx
Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations
Low
Report
Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations